review glp-1 Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping A new review by Clifford

Document vital signs if obtainable (home blood pressure readings), review relevant labs, assess for contraindications

We created this guide to help you learn more about what they are, how to get started and what to expect if your doctor prescribes a GLP-1 for you

Census Bureau

The study showed a 13% reduction in major adverse cardiovascular events (MACE), a composite endpoint for cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, in patients treated with liraglutide compared with placebo at a mean follow-up of 3.8 years (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.780.97) and a significant reduction in cardiovascular death (HR 0.78, 95% CI 0.660.93)

This article examines the current evidence on GLP-1 and brain fog, explores possible mechanisms, and provides guidance on managing cognitive symptoms while using these medications

This page compiles the actual numbers from pooled clinical trial analyses and long-term outcome studies, without minimising the effects that do warrant monitoring